Volume 10, Issue 1 pp. 43-49

Original Article

Effect of AMP-activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population

PRKAA2基因多态性对中国人群易感2型糖尿病和糖尿病肾病的影响研究

Qingchu LI,

Qingchu LI

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Cuilin Li,

Cuilin Li

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Search for more papers by this author

Haoyun Li,

Haoyun Li

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Liu Zeng,

Liu Zeng

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Search for more papers by this author

Zhiqiang Kang,

Zhiqiang Kang

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Yu Mao,

Yu Mao

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Xinyue Tang,

Xinyue Tang

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Search for more papers by this author

Panpan Zheng,

Panpan Zheng

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Li He,

Li He

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Fang Luo,

Fang Luo

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Zhi Li,

Corresponding Author

Zhi Li

[email protected]

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Correspondence

Zhi Li, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Xiangya Road #110, Changsha, Hunan 410078, China.

Tel: +86 731 8480 5380

Fax: +86 731 8235 4476

Email: [email protected]

Search for more papers by this author

Qingchu LI,

Qingchu LI

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Cuilin Li,

Cuilin Li

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Search for more papers by this author

Haoyun Li,

Haoyun Li

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Liu Zeng,

Liu Zeng

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Search for more papers by this author

Zhiqiang Kang,

Zhiqiang Kang

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Yu Mao,

Yu Mao

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Xinyue Tang,

Xinyue Tang

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Search for more papers by this author

Panpan Zheng,

Panpan Zheng

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Li He,

Li He

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Fang Luo,

Fang Luo

Department of Key Laboratory of Endocrinology, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Department of Medical Center Transformation, Zhengzhou Central Hospital, Zhengzhou University, Zhengzhou, China

Search for more papers by this author

Zhi Li,

Corresponding Author

Zhi Li

[email protected]

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China

Correspondence

Zhi Li, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Xiangya Road #110, Changsha, Hunan 410078, China.

Tel: +86 731 8480 5380

Fax: +86 731 8235 4476

Email: [email protected]

Search for more papers by this author

First published: 21 March 2017

https://doi.org/10.1111/1753-0407.12553

Citations: 10

Share a link

Email
Wechat
Bluesky

Abstract

Background

It is well known that AMP-activated protein kinase (AMPK) is a key factor affecting the development of type 2 diabetes mellitus (T2DM). The single nucleotide polymorphism (SNP) rs2746342 in the AMPK alpha 2 subunit gene (PRKAA2) has been found to be associated with susceptibility to T2DM in the Chinese Han population. The present study further investigates the association of PRKAA2 genotypes with susceptibility to T2DM and its complication, diabetic nephropathy.

Methods

The PRKAA2 genotypes of 406 T2DM patients and 214 controls from the Chinese Han population were determined with regard to SNPs rs10789038, rs2796498 and rs2746342. The association between these SNPs and susceptibility to T2DM and diabetic nephropathy was evaluated. The clinical characteristics differed significantly between T2DM patients and controls.

Results

After adjustment for age, sex and body mass index, there was an obvious relationship between T2DM and both rs10789038 (odds ratio [OR] 1.634; P = 0.015) and rs2796498 (OR 0.656; P = 0.030), but not rs2746342. There was haplotype association of PRKAA2 rs10789038–rs2796498–rs2746342 with T2DM susceptibility. In addition, rs2796498 was found to be related to the susceptibility to diabetic nephropathy.

Conclusions

Polymorphisms in rs10789038 and rs2796498 are associated with the susceptibility to T2DM, and rs2796498 may be related to diabetic nephropathy.

摘要

背景

众所周知, AMPK是影响2型糖尿病发生发展的关键基因。有报道称AMPK亚基a2基因(AMPK alpha 2 subunit gene,PRKAA2)rs2746342与中国汉族人群2型糖尿病的易感性相关。本研究旨在进一步探究PRKAA2的基因多态性与2型糖尿病及其并发症糖尿病肾病易感性之间的关联。

方法

我们对来自中国汉族的406个2型糖尿病患者和214个正常健康对照PRKAA2 基因的rs10789038、rs2796498和rs2746342三个多态性位点进行了检测, 并分析了这些SNP与2型糖尿病以及糖尿病肾病易感性的相关性。2型糖尿病患者组和健康对照组的临床特征存在显著差异。

结果

在校正了年龄, 性别和体重指数之后, 2型糖尿病的易感性与rs10789038(OR = 1.634, P = 0.015)和rs2796498(OR = 0.656, P=0.030)两个位点存在显著相关性, 而与rs2746342的基因多态性没有明显关联。同时, PRKAA2 rs10789038-rs2796498-rs2746342的单倍型也与2型糖尿病的易感性相关。除此之外, rs2796498的基因多态性和糖尿病肾病的易感性相关。

结论

PRKAA2基因的rs10789038和rs2796498的基因多态性与2型糖尿病的易感性相关, 同时rs2706498基因多态性可能和糖尿病肾病的易感性相关。

Supporting Information

References

1 World Health Organization. Diabetes Factsheet. 2013. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed 18 September 2014).
Google Scholar
2 Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103: 137–149.
10.1016/j.diabres.2013.11.002
CAS PubMed Web of Science® Google Scholar
3 Zhang BB, Zhou G, LI C. AMPK: An emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009; 9: 407–416.
10.1016/j.cmet.2009.03.012
CAS PubMed Web of Science® Google Scholar
4 Shirwany NA, Zou MH. AMPK in cardiovascular health and disease. Acta Pharmacol Sin. 2010; 31: 1075–1084.
10.1038/aps.2010.139
CAS PubMed Web of Science® Google Scholar
5 Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009; 89: 1025–1078.
10.1152/physrev.00011.2008
CAS PubMed Web of Science® Google Scholar
6 Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005; 26: 69–76.
10.1016/j.tips.2004.12.011
CAS PubMed Web of Science® Google Scholar
7 Carling D. The AMP-activated protein kinase cascade: A unifying system for energy control. Trends Biochem Sci. 2004; 29: 18–24.
10.1016/j.tibs.2003.11.005
CAS PubMed Web of Science® Google Scholar
8 Zang M, Zuccollo A, Hou X et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem. 2004; 279: 47898–47905.
10.1074/jbc.M408149200
CAS PubMed Web of Science® Google Scholar
9 Viollet B, AndreellI F, Jorgensen SB et al. Physiological role of AMP-activated protein kinase (AMPK): Insights from knockout mouse models. Biochem Soc Trans. 2003; 31: 216–219.
10.1042/bst0310216
CAS PubMed Web of Science® Google Scholar
10 Viollet B, AndreellI F, Jorgensen SB et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest. 2003; 111: 91–98.
10.1172/JCI16567
CAS PubMed Web of Science® Google Scholar
11 HorikoshI M, Hara K, OhashI J et al. A polymorphism in the AMPKalpha2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population. Diabetes. 2006; 55: 919–923.
10.2337/diabetes.55.04.06.db05-0727
CAS PubMed Web of Science® Google Scholar
12 MorI Y, Otabe S, Dina C et al. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p. Diabetes. 2002; 51: 1247–1255.
10.2337/diabetes.51.4.1247
CAS PubMed Web of Science® Google Scholar
13 Sun MW, Lee JY, de Bakker PI et al. Haplotype structures and large-scale association testing of the 5′ AMP-activated protein kinase genes PRKAA2, PRKAB1, and PRKAB2 [corrected] with type 2 diabetes [published erratum appears in Diabetes. 2006; 55: 1904]. Diabetes. 2006; 55: 849–855.
10.2337/diabetes.55.03.06.db05-1418
CAS PubMed Web of Science® Google Scholar
14 Shen JZ, Ge WH, Fang Y, Liu H. A novel polymorphism in PRKAA2 is associated with type 2 diabetes in the Han Chinese population. J Diabetes. Epub 11 August 2016. https://doi.org/10.1111/1753-0407.12449.
Google Scholar
15 Bennett PH. Impact of the new WHO classification and diagnostic criteria. Diabetes Obes Metab. 1999; 1 (Suppl. 2): S1–S6.
10.1046/j.1463-1326.1999.0010s2001.x
PubMed Web of Science® Google Scholar
16 Chen F, LI Y, Yang L, Zhong C, Zhuang Z. Association of NOS2 and NOS3 gene polymorphisms with susceptibility to type 2 diabetes mellitus and diabetic nephropathy in the Chinese Han population. IUBMB Life. 2016; 68: 516–525.
10.1002/iub.1513
CAS PubMed Web of Science® Google Scholar
17 Xiao D, Guo Y, LI X et al. The impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms on metformin therapeutic efficacy in Chinese type 2 diabetes patients. Int J Endocrinol. 2016; 2016: 1–7.
Web of Science® Google Scholar
18 Dong M, Gong ZC, DaI XP et al. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2. Clin Exp Pharmacol Physiol. 2011; 38: 824–829.
10.1111/j.1440-1681.2011.05610.x
CAS PubMed Web of Science® Google Scholar
19 LeI T, Tang W, Xiong Y, DI Y, Zhang K, Shu X. Association of TLR4 gene polymorphisms with susceptibility to type 2 diabetes mellitus in the Chinese Han population. Int Immunopharmacol. 2015; 24: 68–71.
10.1016/j.intimp.2014.11.007
CAS PubMed Web of Science® Google Scholar
20 LI Z, Zhang Z, He Z et al. A partition–ligation–combination–subdivision EM algorithm for haplotype inference with multiallelic markers: Update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009; 19: 519–523.
10.1038/cr.2009.33
CAS PubMed Web of Science® Google Scholar
21 Lin L, FlisikowskI K, Schwarzenbacher H et al. Characterization of the porcine AMPK alpha 2 catalytic subunit gene (PRKAA2): Genomic structure, polymorphism detection and association study. Anim Genet. 2010; 41: 203–207.
10.1111/j.1365-2052.2009.01971.x
CAS PubMed Web of Science® Google Scholar
22 Keshavarz P, Inoue H, Nakamura N, Yoshikawa T, TanahashI T, Itakura M. Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK alpha2-subunit (PRKAA2) and risk of type 2 diabetes. Mol Genet Metab. 2008; 93: 200–209.
10.1016/j.ymgme.2007.08.125
CAS PubMed Web of Science® Google Scholar
23 Spencer-Jones NJ, Ge D, Snieder H et al. AMP-kinase alpha2 subunit gene PRKAA2 variants are associated with total cholesterol, low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol in normal women. J Med Genet. 2006; 43: 936–942.
10.1136/jmg.2006.041988
CAS PubMed Web of Science® Google Scholar
24 Tuttle KR, Bakris GL, Bilous RW et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care. 2014; 37: 2864–2883.
10.2337/dc14-1296
PubMed Web of Science® Google Scholar
25 Gupta S, Mehndiratta M, Kalra S, Kalra OP, Shukla R, Gambhir JK. Association of tumor necrosis factor (TNF) promoter polymorphisms with plasma TNF-α levels and susceptibility to diabetic nephropathy in North Indian population. J Diabetes Complications. 2015; 29: 338–342.
10.1016/j.jdiacomp.2015.01.002
PubMed Web of Science® Google Scholar
26 CaI W, LI J, Xu J et al. Association of 2184AG polymorphism in the RAGE gene with diabetic nephropathy in Chinese patients with type 2 diabetes. J Diabetes Res. 2015; 2015: 1–6.
10.1155/2015/310237
Web of Science® Google Scholar
27 HY W, Wang Y, Chen M et al. Association of ELMO1 gene polymorphisms with diabetic nephropathy in Chinese population. J Endocrinol Invest. 2013; 36: 298–302.
PubMed Web of Science® Google Scholar

Citing Literature

Volume10, Issue1

January 2018

Pages 43-49

This article also appears in:

Epidemiology & Genetics

Filename	Description
jdb12553-sup-0001-FigureS1.tifTIFF image, 214.5 KB	Figure S1. Values of D′ between single nucleotide polymorphisms rs10789038–rs2796498, rs10789038–rs2746342, and rs2796498–rs2746342.
jdb12553-sup-0001-FigureS2.tifTIFF image, 125.8 KB	Figure S2. Values of r ² between single nucleotide polymorphisms rs10789038–rs2796498, rs10789038–rs2746342, and rs2796498–rs2746342.

Effect of AMP-activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population

PRKAA2基因多态性对中国人群易感2型糖尿病和糖尿病肾病的影响研究

Abstract

Background

Methods

Results

Conclusions

摘要

背景

方法

结果

结论

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effect of AMP-activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population

PRKAA2基因多态性对中国人群易感2型糖尿病和糖尿病肾病的影响研究

Abstract

Background

Methods

Results

Conclusions

摘要

背景

方法

结果

结论

Supporting Information

References

Citing Literature

References

Related

Information